Pomdoctor Limited, a Guangzhou, China-based digital healthcare company whose Class A ordinary shares trade on the Nasdaq under the ticker POM, has virtually no institutional analyst coverage. Data aggregators list zero covering analysts and no consensus price target for the name, and the few "targets" that circulate online are AI-generated model outputs (such as $0.83 or $1.50) rather than the work of identifiable human analysts at named firms.
Because no reliable analyst consensus exists, the $2.80 objective used in this article is drawn from technical market structure and public discussion, not from analyst forecasts. The stock's 200-day moving average sits near $2.83, a widely followed long-term trend benchmark that POM currently trades well below. The stock also traded as high as roughly $2.95 to $3.01 in late October 2026, so $2.80 represents a return toward a durable technical level and the upper end of the recent range — a plausible "round-trip" objective rather than an arbitrary headline figure.
At a recent close near $1.81, POM would need to rise about 55% to reach $2.80 — a very large move. The shares have been extraordinarily volatile: the 52-week range spans roughly $0.433 to $103.50, and the stock surged from around $0.43 to above $3.00 within October 2026 before settling back. This is a micro-cap situation (market capitalization of only about $5 million) where thin liquidity and low float can produce outsized percentage swings in either direction.
On fundamentals, Pomdoctor operates an online medical-services platform focused on chronic-disease management, internet-hospital consultations, and pharmaceutical supply-chain services. Per Yahoo Finance data, the company reported trailing-twelve-month revenue of roughly $410 million but a net loss of about $370 million, diluted EPS (earnings per share) near negative $40, negative book value, and total debt of roughly $450 million. In short, the path to $2.80 would likely be driven by technical recovery and sentiment rather than near-term profitability.
The most relevant technical anchors are the 50-day moving average near $1.05, the 200-day moving average near $2.83, and the October 2026 swing high around $3.01. Below the current price, the $1.00 level is psychologically and regulatorily significant because of the Nasdaq minimum-bid rule; the recent 52-week low near $0.433 marks the extreme downside. Above the $2.83–$3.00 zone, there is little durable resistance in the near term, but the stock's long-term downtrend — down roughly 98% over the past year — suggests any rally faces substantial overhead supply from prior holders.
Analyst price targets typically reflect a roughly 12-month research horizon, but because no such targets exist for POM, this technical objective has no fixed timetable. Investors should monitor the next earnings release (estimated for late November 2026), any further changes to share count or capital raises, Nasdaq compliance updates, partnership or guidance announcements, and whether the stock can hold above the $1.00 level while working toward the $2.83 moving-average zone.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from shifting market conditions, technical behavior, and AI-driven analysis. For a hyper-volatile, thinly covered name like POM, such automated monitoring can help traders spot changing trends and manage positions more efficiently than manual screening alone. Traders can use these signals to surface new opportunities, track existing holdings, and identify momentum shifts as they develop.
The question of whether POM can reach $2.80 ultimately hinges on technical recovery rather than analyst conviction, because no credible analyst consensus exists for this micro-cap. A roughly 55% advance is very large, yet the stock's own October surge toward $3.00 shows such moves are not unprecedented here. Support comes from restored Nasdaq compliance and a long-term online-healthcare growth story, while the obstacles are severe: deep losses, negative equity, heavy debt, dilution, and extreme illiquidity. The $2.80 objective should be read as a technical milestone — the 200-day moving average and prior trading range — not as a forecast. Investors should focus on earnings, capital-structure changes, and whether the stock can hold above $1.00 before any durable re-rating is plausible.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that POM and SCNX have been poorly correlated (+9% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that POM and SCNX's prices will move in lockstep.
| Ticker / NAME | Correlation To POM | 1D Price Change % | ||
|---|---|---|---|---|
| POM | 100% | N/A | ||
| SCNX - POM | 9% Poorly correlated | -0.40% | ||
| PETS - POM | 4% Poorly correlated | +2.56% | ||
| RDGT - POM | 2% Poorly correlated | N/A | ||
| HKPD - POM | -3% Poorly correlated | -5.15% | ||
| HITI - POM | -11% Poorly correlated | -3.38% |
| Ticker / NAME | Correlation To POM | 1D Price Change % |
|---|---|---|
| POM | 100% | N/A |
| Drugstore Chains industry (5 stocks) | 66% Loosely correlated | -4.08% |